URGN
$33.91-0.38%
UroGen Pharma Ltd.Stock · HealthcareRussell 2000 · 0.05% of IWMNasdaq Composite · 0.004% of ONEQRussell 3000 · 0.003% of IWV
URGN financial statements
The full income statement, balance sheet, and cash-flow statement for UroGen Pharma Ltd. (URGN), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 42.1M2024-09 42.2M2024-12 46.1M2025-03 46.1M2025-06 46.3M2025-09 46.8M2025-12 48.7M2026-03 48.7M2026-06 48.9M+16.1% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 110M+21.4% | 90.4M+9.3% | 82.7M+28.5% | 64.4M+34.0% | 48.0M+307.2% | |
| 97.3M+19.4% | 81.5M+11.1% | 73.4M+29.4% | 56.7M+32.2% | 42.9M+297.5% | ||
| Cost of revenue | 12.4M+40.2% | 8.88M-5.1% | 9.36M+22.3% | 7.65M+48.4% | 5.16M+411.1% | |
| Research & development | 67.1M+17.4% | 57.1M+25.3% | 45.6M-13.8% | 52.9M+11.0% | 47.6M+0.7% | |
| Selling, general & administrative | 155M+28.0% | 121M+29.9% | 93.3M+12.6% | 82.8M-5.4% | 87.5M-3.0% | |
| Operating income | -125M-29.0% | -96.8M-47.7% | -65.5M+17.1% | -79.0M+14.4% | -92.3M+27.2% | |
| Interest & investment income | 5.96M-33.0% | 8.90M+237.0% | 2.64M+181.6% | 938K+157.0% | 365K-81.6% | |
| Other non-operating income | -670K-192.6% | -229K-127.3% | 838K+1063.9% | 72.0K+147.1% | -153K | |
| Pre-tax income | -153M-23.7% | -124M-26.2% | -98.3M+9.0% | -108M+1.2% | -109M+12.6% | |
| Income tax | 78.0K-97.2% | 2.83M-27.8% | 3.92M+123.4% | 1.75M+21.1% | 1.45M-57.1% | |
| Net income | -153M-21.0% | -127M-24.1% | -102M+6.9% | -110M+0.9% | -111M+13.7% | |
| EPS (basic) | -$3.19-7.8% | -$2.96+16.6% | -$3.55+26.2% | -$4.81+3.0% | -$4.96 | |
| Weighted-avg shares (basic) | 48.1M+12.2% | 42.9M+48.7% | 28.8M+26.4% | 22.8M+2.1% | 22.3M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 186M-32.6% | 276M+63.2% | 169M+31.2% | 129M+12.7% | 114M-1.1% | ||
| Cash & equivalents | 111M-35.6% | 172M+81.0% | 95.0M+71.5% | 55.4M+24.9% | 44.4M-16.1% | |
| Short-term investments | 49.3M-55.4% | 111M+97.1% | 56.2M | — | — | |
| Cash & short-term investments | 121M-50.1% | 242M+70.8% | 142M | — | 66.9M | |
| Accounts receivable | 33.1M+62.9% | 20.3M+31.5% | 15.4M+21.6% | 12.7M+8.4% | 11.7M+66.3% | |
| Inventory | 16.5M+78.4% | 9.23M+62.6% | 5.67M+31.2% | 4.33M-10.5% | 4.83M+146.0% | |
| Prepaid expenses | 14.7M+65.9% | 8.85M-14.0% | 10.3M-7.4% | 11.1M+48.5% | 7.48M+122.2% | |
| 200M-29.8% | 286M+60.2% | 178M+31.5% | 136M+13.3% | 120M-1.9% | ||
| Property, plant & equipment | 637K-2.7% | 655K-4.9% | 689K-46.9% | 1.30M-34.1% | 1.97M-3.9% | |
| Operating lease right-of-use | 3.08M+262.8% | 849K-49.2% | 1.67M-31.9% | 2.45M+107.8% | 1.18M-45.3% | |
| Other non-current assets | 5.16M+776.2% | 589K-71.1% | 2.04M-25.6% | 2.74M+109.0% | 1.31M+1886.4% | |
| 46.4M+1.0% | 45.9M+47.2% | 31.2M+30.5% | 23.9M+6.9% | 22.4M+4.4% | ||
| Accounts payable | 12.1M+11.0% | 10.9M+67.8% | 6.51M+17.9% | 5.53M-4.5% | 5.79M+76.9% | |
| Accrued liabilities | 27.7M+1.0% | 27.4M+65.9% | 16.5M+33.6% | 12.4M+2.3% | 12.1M+20.7% | |
| Current lease liability | 481K-38.7% | 785K-4.2% | 819K | — | — | |
| Other current liabilities | 3.43M-56.8% | 7.95M+105.9% | 3.86M+17.8% | 3.28M-1.6% | 3.33M+79.1% | |
| Finance lease liability (current) | 1.27M+71.0% | 745K | 0.00 | — | — | |
| 306M+3.9% | 295M+20.9% | 244M+8.2% | 225M+102.1% | 111M+334.0% | ||
| Long-term debt | 122M+0.4% | 122M+23.5% | 98.6M+1.0% | 97.5M | 0.00 | |
| Non-current lease liability | 2.65M+4463.8% | 58.0K-93.1% | 844K-46.8% | 1.59M+298.5% | 398K-73.4% | |
| Operating lease liability (total) | 3.13M+120.8% | 1.42M-14.9% | 1.66M-34.2% | 2.53M+69.9% | 1.49M-44.9% | |
| Finance lease liability (total) | 4.75M+103.0% | 2.34M | — | — | — | |
| Finance lease liability | 3.48M+117.9% | 1.59M+89.0% | 844K | — | — | |
| -105M-1098.2% | -8.80M+86.5% | -65.2M+27.0% | -89.4M-1162.2% | 8.41M-91.3% | ||
| Common stock | 133K+15.7% | 115K+29.2% | 89.0K+41.3% | 63.0K+3.3% | 61.0K+1.7% | |
| Additional paid-in capital | 854M+7.1% | 797M+29.8% | 614M+25.9% | 488M+2.5% | 476M+5.1% | |
| Retained earnings | -960M-19.0% | -806M-18.7% | -679M-17.7% | -577M-23.5% | -467M-31.1% | |
| Accumulated other comprehensive income | 19.0K-66.1% | 56.0K+366.7% | 12.0K+111.2% | -107K-328.0% | -25.0K-109.2% | |
| Total liabilities & equity | 200M-29.8% | 286M+60.2% | 178M+31.5% | 136M+13.3% | 120M-1.9% | |
| Common shares issued | 48.4M+14.5% | 42.2M+30.0% | 32.5M+40.5% | 23.1M+3.0% | 22.5M+1.3% | |
| Common shares outstanding | 48.4M+14.5% | 42.2M+30.0% | 32.5M+40.5% | 23.1M+3.0% | 22.5M+1.3% | |
| Shares outstanding (cover) | 48.7M+5.6% | 46.1M+35.1% | 34.1M+45.6% | 23.4M+3.4% | 22.7M+1.8% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -162M-67.9% | -96.8M-26.7% | -76.4M+12.8% | -87.6M-3.1% | -84.9M+19.8% | ||
| Depreciation & amortization | 307K-6.7% | 329K-59.0% | 802K-13.2% | 924K+11.2% | 831K+99.8% | |
| Share-based compensation | 12.0M-8.8% | 13.1M+40.3% | 9.34M-11.7% | 10.6M-54.2% | 23.1M-17.5% | |
| Change in receivables | 12.8M+163.0% | 4.86M+77.4% | 2.74M+177.5% | 987K-78.9% | 4.67M-33.7% | |
| Change in inventory | 7.24M+103.6% | 3.55M+163.6% | 1.35M+272.4% | 362K-87.4% | 2.87M+46.0% | |
| 61.6M+398.6% | -20.6M-2063.0% | -953K-189.9% | 1.06M-73.9% | 4.07M-95.6% | ||
| Capital expenditure | 289K-2.0% | 295K+52.1% | 194K-23.6% | 254K-66.2% | 752K-38.1% | |
| Free cash flow | -163M-67.7% | -97.1M-26.8% | -76.6M+12.8% | -87.8M-2.5% | -85.6M+20.0% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales/maturities of investments | 139M+29.3% | 108M+119.5% | 49.1M-23.7% | 64.3M+18.6% | 54.3M-56.3% | |
| 39.9M-79.5% | 195M+66.4% | 117M+20.4% | 97.1M+34.3% | 72.3M+337.6% | ||
| Long-term debt issued | 0.00-100.0% | 24.5M | 0.00-100.0% | 95.8M | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 39.8M-73.7% | 151M+124.4% | 67.4M | 0.00 | 0.00-100.0% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | -61.0M-178.9% | 77.2M+95.0% | 39.6M+272.4% | 10.6M+225.1% | -8.50M-319.2% | |
| Income taxes paid | 3.00M+66.7% | 1.80M | — | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.14B+132.3% | 491M+6.0% | 463M+126.1% | 205M-5.0% | 216M-46.3% | |
| P/S | 10.4×+91.2% | 5.4×-9.4% | 6.0×+82.7% | 3.3×-26.9% | 4.5×-86.8% | |
| P/B | — | — | — | — | 25.6×+515.2% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: URGN’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all URGN filings on SEC EDGAR → Not investment advice.